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Abstract This study presents the in vitro hydrodynamic
assessment of the TRISKELE, a new system suitable for
transcatheter aortic valve implantation (TAVI), aiming to
mitigate the procedural challenges experienced with cur-
rent technologies. The TRISKELE valve comprises three
polymeric leaflet and an adaptive sealing cuff, supported
by a novel fully retrievable self-expanding nitinol wire
frame. Valve prototypes were manufactured in three sizes
of 23, 26, and 29 mm by automated dip-coating of a
biostable polymer, and tested in a hydrodynamic bench
setup in mock aortic roots of 21, 23, 25, and 27 mm
annulus, and compared to two reference valves suitable
for equivalent implantation ranges: Edwards SAPIEN
XT and Medtronic CoreValve. The TRISKELE valves
demonstrated a global hydrodynamic performance compa-
rable or superior to the controls with significant reduction
in paravalvular leakage. The TRISKELE valve exhibits
enhanced anchoring and improved sealing. The valve is
currently under preclinical investigation.
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Abbreviations
ΔP Transvalvular systolic pressure drop
CO Cardiac output
EOA Effective orifice area
TAVI Transcatheter aortic valve implantation
POSS Polyhedral oligomeric silsesquioxanes
PCU Poly(carbonate-urea) urethane
UCL University College London
Introduction
Transcatheter aortic valve implantation (TAVI) has evolved to
become the standard treatment for inoperable and high-risk
patients with severe aortic stenosis [1–3], accounting for more
than 20% of global aortic valve replacement procedures [4, 5].
In intermediate-risk patients, TAVI has shown clinical out-
comes and survival rates similar or superior to surgical aortic
valve replacement [6–8]. However, further developments are
still necessary to overcome technical and procedural chal-
lenges such as secure deployment and correct positioning of
the prosthesis, common presence of paravalvular leakage [9,
10], frequent changes in atrioventricular conduction [11], dif-
ficulties in vascular access, embolization, and risk of stroke
[12, 13]. More recently, there have been reports concerning
possible subclinical leaflet thrombosis and reduced leaflet
motion [14].
Chemically treated bovine and porcine pericardium are
commonly used as leaflet material for TAVI valves, based on
their broad and successful clinical history in surgical
bioprostheses [15]. Nevertheless, the durability of
bioprosthetic leaflets is still a matter of debate [16–18]. The
nonphysiological stresses, applied to the leaflets of TAVI pros-
theses during crimping and deployment, cause tissue dehydra-
tion and are believed to increase the risk of structural damage
[19–21], affecting adversely the durability of the pericardial
valves [22–26]. Polymeric heart valves could represent an
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attractive alternative to xenograft tissues, addressing these
limitations. Although no polymeric valve has reached the mar-
ket yet, mainly due to their limited durability and
hemocompatibility [27], recent advances in biomaterial sci-
ence, surface modification techniques, prosthetic design, and
fabrication methods have contributed to the development
of new synthetic materials more suitable for valvular
applications [28–30].
This study describes the in vitro hydrodynamic assessment
of a new transcatheter heart valve concept, recently developed
at UCL. The TRISKELE is a self-expanding valve with poly-
meric leaflets, aiming to mitigate complications related to im-
precise valve positioning and provide a more reliable solution
for both high risk patients with severe aortic stenosis and
additionally the lower risk patient demographics at a lower
cost.
Methods
Valve Description
The TRISKELE valve is designed based on a self-expanding
wire frame formed by thermomechanical shaping of three sets
of nitinol wires mechanically joined by stainless steel
crimping sleeves. The outflow portion of wire frame features
three lateral ribs defined by sets of smoothly arched petal-like
shapes that protrude radially further than the flow-control
structure (Fig. 1). This geometrical feature helps maintain an
open structure which reduces the impact on the surrounding
tissue and dampens the pressure load transferred to the leaflets
while functioning. The advantages of the TRISKELE delivery
system has been previously described in detail [31]. The frame
design was optimized numerically for three nominal sizes of
23, 26, and 29 mm, aiming at minimizing operating stresses
and maintaining secure anchoring under conservative physio-
logical pressure levels.
The TRISKELE leaflets design is based on a novel princi-
ple successfully adopted previously for surgical tri-leaflets
heart valves [32], which aims to achieve a single curvature
in both the open and closed unloaded configurations. This
approach has been shown to reduce the energy dissipated dur-
ing the operating cycle, resulting in an improved hydrody-
namic performance and reduced stress levels. Polyhedral olig-
omeric silsesquioxanes poly(carbonate-urea) urethane (POSS-
PCU) was used to manufacture the leaflets and the sealing
components of the TRISKELE valve. This is a nanocomposite
polymer consisting of a hard crystalline segment and soft elas-
tomeric segments in which polyhedral oligomeric
silsesquioxanes (POSS) nanoparticles are attached as pendant
chain functional groups to the backbone of poly(carbonate-
urea) urethane (PCU). POSS-PCU has been previously vali-
dated in vitro for its hemocompatibility and anti-
thrombogenicity [33–35], biostability [33], mechanical prop-
erties [36, 37], and resistance to calcification [38]. The leaflets
and sealing cuff were manufactured using a new automated
manufacturing technique developed in-house, which enables
the construction of highly reproducible polymeric valves
(Fig. 2) by robotic dip-coating of a stainless steel mandrel into
an 18% (w/v) polymer solution. This manufacturing approach
is suitable for a wide range of biostable polymers that can be
used in combination or as an alternative to POSS-PCU.
The valve includes a skirt, supporting a flexible chalice
shape sealing cuff departing from the skirt and surrounding
the entire valve. The lower portion of the cuff is fixed with
continuity to the valve skirt along a scalloped peripheral line,
leaving the rest of the cuff free to adapt to the irregularity of
the host interface (left ventricular outflow tract and native
aortic leaflets) (Fig. 1) under the effect of the pressure differ-
ence between the aorta and the ventricle. The inflow portion of
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Fig. 1 The TRISKELE
transcatheter aortic valve
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the skirt, below the sealing cuff, is fenestrated to reduce the
stress in the polymer during crimping, and promote cell
integration.
The geometrical dimensions of the TRISKELE valves of
the currently available sizes are illustrated in Fig. 2.
Hydrodynamic Assessment
In vitro bench tests were performed to evaluate the hydrody-
namic function of the TRISKELE valves using a commercial
cardiovascular pulse-duplicator (Vivitro Superpump System
SP3891, Vivitro, Victoria, BC, Canada), reproducing physio-
logically equivalent aortic pressures and flows [39]. The
pulse-duplicator was modified by incorporating a mock sili-
cone aortic root based on the description provided by
Swanson and Clark [40] inside the aortic chamber (Fig. 3a).
The compliant aortic root compartments, developed in-house,
include three cast rubber leaflets designed based on the dimen-
sions and geometric relationships of the human aortic valve
[41], replicating the presence of the native valve during the
test. Mock aortic roots of 21-, 23-, 25-, and 27-mm annulus
diameter were constructed to cover the recommended implan-
tation ranges for all studied valve sizes. An additional bulged
section was also included below the aortic annulus, to repro-
duce the ventricular outflow tract. In order to approximate
calcific native tissues, common in TAVI applications, the se-
lected root compliance for the testing pressure range was low-
er than 0.05% per mmHg, based on the definition in the ISO
5840 [39, 42].
Two commercially available TAVI valves, the Edwards
SAPIEN XT (n = 1, per size) and the Medtronic CoreValve
(n = 1, per size), were included in the study as controls, tested
according to their manufacturer’s recommended implantation
range guide.
All valves were tested in 37 °C buffered saline solution
(0.90% w/v NaCl) at increasing cardiac output (COs) of 2,
3, 4, 5, 6, and 7 l/min, with a mean arterial pressure of
100 mmHg, a fixed heart rate of 70 beats per minute, and
systole occupying 35% of the cardiac cycle [39].
Figure 3b shows a typical diagram of pressures and flows
generated over a cardiac cycle at a CO of 5 l/min. Once
the mean arterial pressure and the cardiac output flow
readings stabilized, measurements of atrial, ventricular,
and aortic pressures and aortic flow were collected and
averaged over ten consecutive cardiac cycles. Based on
these recordings, the mean transvalvular systolic pressure
drop (ΔP) and the regurgitant fraction were determined.
The regurgitant fraction represents the total regurgitant
volume expressed as a percentage of the stroke volume.
The total regurgitant volume is the sum of the closing
regurgitant volume, associated with the dynamic of valve
closure, and the leakage regurgitant volume, correspond-
ing to the leakage through the closed valve (in the case of
TAVI devices, it can be essentially attributed to
paravalvular leakage). Effective orifice area (EOA), which
represents the minimal cross-sectional area of the down-
stream jet at the aortic valve orifice [43], was derived
from the continuity equation, applying Gorlin’s formula
[44]. The fluid-mechanical left ventricular energy loss as-
sociated with the valve was calculated as the time integral
of the product of the mean systolic pressure drop and
aortic flow, over the different phases of the cardiac cycle
[39]. The energy loss value quantifies the overall impact
of the valve performance on the myocardial function [45],
taking into account the losses associated with both pres-
sure drop during systole and the regurgitation during di-
astole. Data are presented in mean ± standard deviation
(n = 3, per size of the TRISKELE valves).
Results
Aortic Root Size 21
In the 21-mm aortic root, the size 23 TRISKELE valves
were slightly more constricted than the controls, resulting
? 23 ? 26 ? 29
30 33
36
Fig. 2 TRISKELE valve sizes 23
(left), 26 (center), and 29 (right).
The automated manufacturing
technique, developed in-house,
facilitates consistent production
of TRISKELE valves with a mean
leaflet thickness of 130 ± 10 μm.
The height and nominal diameter
of TRISKELE valves are noted
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in a relatively higher transvalvular pressure drop (Fig. 4a).
At lower COs, the TRISKELE-23 had a similar ΔP to
those of the control valves but showed higher relative
pressure gradient as the CO increased. The mean ΔP over
the entire CO range was measured as 20.2, 14.5, 15.8, and
11.7 mmHg, while the mean EOA was 1.4, 1.8, 1.7, and
2.0 for the TRISKELE-23, CoreValve-26, SAPIEN-23,
and SAPIEN-26, respectively. The mean regurgitant frac-
tion was 16.7, 25.6, 26.1, and 21.9% (Fig. 5a), with sim-
ilar closing volumes, but leakage volumes of 8.0, 16.3,
16.6, and 12.7 ml measured for the TRISKELE-23,
CoreValve-26, SAPIEN-23, and SAPIEN-26, respectively
(Fig. 6a). The TRISKELE-23 demonstrated a minimal to-
tal energy loss of 384 mJ, similar to SAPIEN-26
(372 mJ), and significantly better than CoreValve-26
(450 mJ) and SAPIEN-23 (506 mJ) (Fig. 7a).
Aortic Root Size 23
In the 23-mm aortic root, the mean ΔP over the entire COs
measured as 14.1, 12.2, 13, and 15.6mmHg, withmean EOAs
of 1.7, 2.1, 2.0, and 1.7 cm2 achieved by the TRISKELE-26,
CoreValve-26, CoreValve-29, and SAPIEN-26, respectively
(Fig. 4b). Frequent ventricular migration was observed for
the CoreValve at CO higher than 3 l/min. Therefore, it was
constrained to the distal end of the aortic root using down-
stream tethers to prevent premature migration to ventricular
chamber. The TRISKELE-26, CoreValve-26, CoreValve-29,
and SAPIEN-26 were performed with mean regurgitant frac-
tions of 15.8, 33.0, 30.8, and 23.9% (Fig. 5b); similar closing
volumes; mean leakage volumes of 6.7, 24.7, 22.6, and
14.2 ml (Fig. 6b); and mean total energy losses of 278, 543,
506, and 449 mJ, respectively (Fig. 7b).
Atrial pressure transducer
Mitral valve
Ventricular pressure
transducer
Annulus diameter
a
b
Aortic pressure
transducer
Fig. 3 a The Vivitro pulse-duplicator system, consisting of a model left
heart, a hydromechanical pump, flow measuring and data acquisition
elements, and a mock aortic root designed to replicate the presence of
the native valve; b a typical diagram of transvalvular pressures/flows over
a cardiac cycle at CO of 5 l/min
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Aortic Root Size 25
In the 25-mm aortic root, the TRISKELE-26, CoreValve-29,
SAPIEN-26, and SAPIEN-29 were associated with mean ΔP
over the entire COs of 11.0, 12.6, 12.2, and 4.6 mmHg, and
mean EOAs of 1.9, 1.1, 2.6, and 3.4 cm2, respectively
(Fig. 4c). Valve migration was observed for both the
CoreValve and SAPIEN-26 (migrated at a Co of 6 l/min).
Hence, both valves were constrained to the aortic root. The
mean regurgitant fraction was measured as 19.3, 35.5, 48.4,
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Fig. 4 Transvalvular pressure
drop (ΔP) (bars, left Y-axis units)
and effective orifice area (points
and connecting lines, right Y-axis
units) measured as a function of
cardiac output (2–7 l/min) in
mock aortic roots of 21 mm (a),
23 mm (b), 25 mm (c), and
27 mm (d) annulus. Data are
expressed as mean ± SD, n = 30
for TRISKELE (three valves,
each tested over 10 cycles) and
n = 10 for control valves (one
valve tested over 10 cycles)
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and 31.4% (Fig. 5c), with 4.9, 4.8, 18.9, and 7.3 ml of closing
regurgitant volume, and 9.1, 27.2, 36.1, and 18.7 ml of leak-
age volumes (Fig. 6c)for the TRISKELE-26, CoreValve-29,
SAPIEN-26, and SAPIEN-29, respectively. In the same order,
these valves experiences mean total energy losses of 301, 606,
940, and 379 mJ (Fig. 7c).
Aortic root 21
2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7
0
20
40
TRISKELE-23           CoreValve-26         SAPIEN XT-23        SAPIEN XT-26
R
e
g
u
r
g
it
a
n
t
 
f
r
a
c
t
io
n
 
(
%
)
Aortic root 23
2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7
0
20
40
60
TRISKELE-26           CoreValve-26          CoreValve-29       SAPIEN XT-26
R
e
g
u
r
g
it
a
n
t
 
f
r
a
c
t
io
n
 
(
%
)
Aortic root 25
2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7
0
20
40
60
80
TRISKELE-26           CoreValve-29           SAPIEN-26          SAPIEN XT-29
R
e
g
u
r
g
it
a
n
t
 
f
r
a
c
t
io
n
 
(
%
)
Aortic root 27
2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7
0
20
40
60
80
TRISKELE-29                      CoreValve-29                 SAPIEN XT-29
R
e
g
u
r
g
it
a
n
t
 
f
r
a
c
t
io
n
 
(
%
)
a
b
c
d
Fig. 5 Total regurgitant fraction
measured as a function of cardiac
output (2–7 l/min) in mock aortic
roots of 21 mm (a), 23 mm (b),
25 mm (c), and 27 mm (d)
annulus. Data are expressed as
mean ± SD, n = 30 for
TRISKELE (three valves, each
tested over 10 cycles) and n = 10
for control valves (one valve
tested over 10 cycles)
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Aortic Root Size 27
In the 27-mm aortic root, the mean ΔP over the entire COs
measured as 9.1, 15.2, and 6.7 mmHg, with mean EOAs of
2.1, 2.3, and 2.5 cm2 recorded for the TRISKELE-29,
CoreValve-29, and SAPIEN-29, respectively (Fig. 4d). In
the same order, these valves were associated with regurgitant
fraction of 19.2, 48.0, and 18.5% (Fig. 5d); closing regurgitant
volumes of 5.7, 15.6, and 6.5 ml; leakage volumes of 7.9,
38.6, and 6.4 ml (Fig. 6d); and total energy losses of 227,
1010, and 218 mJ (Fig. 7d). The CoreValve-29 was
constrained in this aortic root as well.
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Fig. 6 Components of the
regurgitant volume measured as a
function of cardiac output (2–7 l/
min) in mock aortic roots of
21mm (a), 23mm (b), 25mm (c),
and 27 mm (d) annulus. Data are
expressed as mean ± SD, n = 30
for TRISKELE (three valves,
each tested over 10 cycles) and
n = 10 for control valves (one
valve tested over 10 cycles)
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Discussion
This study provided important data on the function and flow
characteristics of the TRISKELE valves, as well as the refer-
ence devices. The valves were implanted in the mock aortic
roots following their intended loading and deployment steps
(the reference valves were implanted in accordance with their
manufacturer’s instructions for use), and tested in pulsatile
setup simulating a wide range of flow conditions over increas-
ing cardiac output of 2–7 l/min. The self-expanding valves,
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Fig. 7 Fluid-mechanical left
ventricular energy loss, calculated
at increasing cardiac output (2–
7 l/min) in mock aortic roots of
21mm (a), 23mm (b), 25mm (c),
and 27 mm (d) annulus. Data are
expressed as mean ± SD, n = 30
for TRISKELE (three valves,
each tested over 10 cycles) and
n = 10 for control valves (one
valve tested over 10 cycles)
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the TRISKELE and the CoreValve, experienced some flow-
induced self-readjustment from their initial implantation posi-
tion while reaching physiologic pressure and flow conditions.
In general, the TRISKELE valves had comparable perfor-
mance with the control valves during systole, with exception
for the 21-mm annulus aortic root, where our study device
exhibited appreciably higher levels of ΔP and worse EOA
than the controls (Fig. 4a). This can be attributed to the
adopted anchoring approach, designed to reduce the radial
forces while enhancing anchoring, which may produce some
overconstraint of the leaflets commissures at the smallest im-
plantation sizes, compared to the reference valves.
Nevertheless, this limitation could be corrected by expanding
the available sizes for the valve to lower diameters.
The SAPIEN valves demonstrated comparatively better
performance in small implantation sizes (21 and 23 mm),
probably due to the fact that this prosthesis, being balloon
expandable, has a stiffer stent which retains a larger EOA after
inflation of the balloon and successive partial recoil. TAVI
prostheses typically operate at a configuration that is smaller
than their fully expanded forms. Once implanted, the function-
al orifice area of a these valves may be limited by the stenotic
native valve leaflets and/or the inner diameter of the diseased
bioprostheses (in the case of valve-in-valve procedure)
[46–48]. The self-expanding stents may be associated with a
relatively smaller EOA, as they are often deformed under the
radial anchoring forces [49].
Common recurrence of paravalvular regurgitation is a ma-
jor drawback of current TAVI valves [9, 10, 50, 51]. The
TRISKELE demonstrated superior performance during dias-
tole, achieving major reduction in paravalvular leakage in all
aortic roots. The sealing cuff incorporated into the TRISKELE
design minimizes the paravalvular leakage by covering the
gaps between the prosthetic and native tissue. Almost all sizes
of the TRISKELE valves achieved a significantly lower total
regurgitation (closing regurgitation and leaking volume) com-
pared to the control valves.
The systolic hydrodynamic function of TAVI valves may
be as good as or even exceed the performance of surgically
implanted bioprostheses [52]; however, their diastolic perfor-
mance is often compromised by paravalvular leakage and
transvalvular regurgitation, resulting in increased energy loss
during diastole [53]. Energy loss measurements provide a
comprehensive criteria to evaluate and compare the overall
hydrodynamic performance of the valves during an entire car-
diac cycle, based on their effect on the ventricular workload
[45]. Higher paravalvular leakage and central regurgitation
have an adverse impact upon valve performance. The lower
total energy loss achieved by the TRISKELE indicates a lesser
fraction of the ventricular workload to operate, when com-
pared to the reference valves.
Both reference valves experienced some form of dislodge-
ment during the tests, which compromised their performance
within the recommended implantation ranges, with the
CoreValves having more frequent migrations at CO higher
than 3 l/min. In these cases, it was only possible to determine
the hydrodynamic performance of the functional components
by Bartificially^ constraining the valves in their initial axial
position, although this was not ideal. These premature migra-
tions may be, to some extent, associated with the absence of
calcific or fibrotic lesions in the in vitro test model and the
smooth surface of the silicone leaflets in the mock aortic roots.
Similar observations have been reported previously in animal
studies [54, 55].
No migration was observed for the TRISKELE valves,
which contrary to the reference devices is secured to the im-
plantation site by applying mainly counteracting axial forces,
rather than radial actions [49]. The lower protrusions of the
frame (inflow portion) project into the left ventricle and the
upper petal-like ribs (outflow portion) expand radially on top
of the valve annulus, into the leaflets of the native valve
(Fig. 1). The valve anchoring is achieved by constraining the
aortic annulus and not by dilating it, thus avoiding the appli-
cation of high levels of distributed radial forces which might
perturb the atrioventricular node and the left bundle branch.
This approach is suitable for application in patients with cal-
cific stenosis, as well as for uncalcified anatomies, as con-
firmed by the successful implants in healthy and compliant
native ovine aortic valve [31].
In an attempt to replicate the presence of stiffened native
cusps, the mock aortic roots used in this study were made with
the same thickness as the root wall. This is, necessarily, an
approximation, as it does not incorporate the surface irregu-
larities produced by the presence of calcific nodules, which
possibly contribute, in vivo, to a more effective retention of
the reference valves. However, the model provides an ideal-
ized configuration, which allows direct comparison of differ-
ent valves under identical anatomical and operating
conditions.
Polymeric leaflets provide more design freedom compared
to industry standard xenografts. Biostable polymers can be
used to produce leaflets two to three times thinner than peri-
cardial tissues, which can potentially result in smaller collaps-
ible valve profile and minimize complications related to vas-
cular access. The thinner polymeric leaflets also improve the
hemodynamics of the valve, making it easier to open and
achieve a larger orifice area [56].
Biostable polymers can be engineered to exhibit a tailored
range of physical, chemical, and biological characteristics.
The α-Gal-free nature of biostable polymers means lower
risks of calcification compared to porcine and bovine tissues
and may lead to potential advantages in terms of long-term
performance and durability [38, 57, 58]. Moreover, there is no
suturing involved in the manufacturing process, hence no
stitch hole in the leaflets which could cause tissue tear in the
flexion zones. Pericardial tissues are reported to be prone to
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dehydration and collagen fiber impairment [22–26].
Polymeric leaflets are less susceptible to physical damage in-
duced as a result of collapsing/crimping, hence can be
preloaded in air long before the operation, without causing
any observable harm to the valve [31].
While new TAVI devices with improved delivery strategies
are being developed, there are both hopes and concerns on
expanding the application of TAVI to less risky patient demo-
graphics [6, 59]. The future of transcatheter heart valve re-
placement and its expansion to lower risk patients depends
on technological advances in biomaterials, anticalcification
treatment, and development of collapsible valves for optimal
delivery and deployment.
Limitations
Isotonic saline was used as testing fluid in this study, which is
less viscous than blood, and results into increased leakage
volumes compared with the clinical cases. Although fluid vis-
cosity is reported to have little influence on systolic perfor-
mance of the test valves, it may affect the leakage flow in an
in vitro setup [60, 61]. Another limitation of this study was the
lack of statistical power due to minimal number of reference
devices (i.e., SAPIEN XT and CoreValve). A larger sample
size is required to ensure adequate representation of the ex-
pected variability in the control group.
Also, it is worth to mention that significant efforts have
been made by TAVI manufacturers to address the recurrences
of paravalvular leakage, and a number of latest generation
transcatheter valves, including the newest member of the
Edwards SAPIEN family (SAPIEN 3), are reported to have
reduced paravalvular leakage compared to the reference
valves used in this study [62].
Conclusion
An in vitro study was performed to evaluate the hydrodynam-
ic function of a new transcatheter heart valve concept, with
polymeric leaflets, an adaptive sealing cuff, and a novel fully
retrievable self-expanding frame. The TRISKELE prototypes
of 23, 26, and 29 nominal diameter were manufactured using a
new automated technique which allows manufacturing of
highly reproducible polymeric valves. The TRISKELE valves
exhibited comparable or superior hydrodynamic performance
compared to the SAPIEN XT (Edwards Lifesciences) and the
CoreValve (Medtronic) devices, when tested in appropriate
annuli (21-, 23-, 25-, and 27-mm diameter). The TRISKELE
valve demonstrated significant reduction in paravalvular leak-
age (independently on the presence of calcification). The sat-
isfactory results from this study encourage the possibility for
further development and refinement. The TRISKELE valve is
currently under preclinical investigation for its durability and
function in chronic animal studies.
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